SCHEMBL4369358

SCHEMBL4369358

Nc1ccc(C2(c3ccc(Cl)cc3)OCCO2)cc1C(=O)c1cccc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.44
MAPT P10636 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
CHEK2 O96017 1/20 0.41
RECQL P46063 1/20 0.40
FADS1 O60427 1/20 0.40
PARP1 P09874 1/20 0.39
CYP26A1 O43174 1/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
CYP26B1 Q9NR63 1/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GFER P55789 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4382647 0.90 MAPT (0.49) ALOX15MAPTTDP1CHEK2RECQL
SCHEMBL12022155 0.90 MAPT (0.51) ALOX15MAPTTDP1CHEK2PARP1
SCHEMBL5780967 0.90 MAPT (0.42) MAPTTDP1CHEK2CYP26A1RXRA
SCHEMBL5518160 0.87 NPC1 (0.44) MAPTTDP1PARP1KMT2AMEN1
SCHEMBL14434166 0.82 MAPT (0.50) MAPTTDP1CHEK2CYP26A1RXRA
SCHEMBL13341961 0.79 CHRNA7 (0.41) ALOX15CHEK2KMT2AMEN1
SCHEMBL6341269 0.79 RECQL (0.60) ALOX15MAPTRECQLFADS1PARP1
SCHEMBL5782815 0.75 TP53 (0.45) MAPTKMT2AMEN1SMN1; SMN2
SCHEMBL12022157 0.74 ALDH1A1 (0.42) MAPTTDP1KMT2AMEN1GAA
SCHEMBL4288792 0.74 MAPT (0.33) ALOX15MAPTTDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1339709-B1 FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2009-06-24 EP disclosed
EP-0977750-B1 FARNESYLTRANSFERASE INHIBITING QUINAZOLINONES JANSSEN PHARMACEUTICA NV (BE) 2007-07-04 EP disclosed
US-7153958-B2 Farnesyl transferase inhibiting benzoheterocyclic derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-26 US disclosed
US-20040034218-A1 Farnesyl transferase inhibiting benzoheterocyclic derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2004-02-19 US disclosed
US-6358961-B1 ADMINISTERING QUINAZOLINE DERIVATIVE FOR INHIBITING TUMOR GROWTH IN MAMMALS JANNSEN-CILAG S.A. (FR) 2002-03-19 US disclosed
US-6177432-B1 ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS JANSSEN-CILAG S.A. (FR) 2001-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034218-A1 Farnesyl transferase inhibiting benzoheterocyclic derivatives FNTA, FNTB, RCE1 ALOX15 1923/4885MAPT 3857/4885TDP1 3431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.